The mortality rate in the extension of CD12 right now in critically ill population is about 16.7%. About 17%. CD12 we had results of 28% in leronlimab, 37% in placebo
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.